Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 80Leukemia, Myeloid, Acute 74Multiple Myeloma 70Breast Neoplasms 70Lymphoma, Non-Hodgkin 62Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 53Burkitt Lymphoma 52Recurrence 51Myelodysplastic Syndromes 50Lymphoma, Follicular 50Lymphoma, B-Cell 47Leukemia 43Triple Negative Breast Neoplasms 40Lymphoma, Mantle-Cell 38Neoplasms 37Hodgkin Disease 34Melanoma 33Lymphoma, B-Cell, Marginal Zone 32Hematologic Neoplasms 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Neuroblastoma 28Ovarian Neoplasms 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Neoplasm Metastasis 22Pancreatic Neoplasms 21Leukemia, Biphenotypic, Acute 21Sarcoma 18Myeloproliferative Disorders 17

Interventions

brivaracetam 1Topotecan 1Sirolimus 1Magnetoencephalography 1LY3295668 erbumine 1Ketamine 1Fentanyl 1Cyclophosphamide 1Clinical Laboratory Techniques 1Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epilepsy × Cyclophosphamide × 1 year × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡